Outcomes of Persistent Microvascular Inflammation in Repeated Kidney Allograft Biopsies
Clinical Transplantation · 2025-12 · 39 (12)
DOI: 10.1111/ctr.70419 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Transplantation, online erschienen am 11.12.2025. Verfasst von Sandesh Parajuli und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA. Hauptthemen laut MEDLINE: Kidney Transplantation, Graft Rejection, Inflammation, Microvessels. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Virginia Lee Cook Foundation.
Abstract (Originalsprache)
Background
Microvascular inflammation (MVI) with sum glomerulitis and peritubular capillaritis (g+ptc) ≥ 2 is an integral component of kidney allograft antibody‐mediated rejection (AMR). It is unclear what the outcomes are among those with persistent MVI, despite treatment.
Methods
We included all kidney transplant recipients (KTRs) with persistent MVI ≥ 2 on first and second allograft biopsies who had third biopsies within 2 years of the first biopsy. KTRs were categorized into two groups, MVI (+) and MVI (−) on third biopsy. Risk factors for persistent MVI ≥ 2 on third biopsy, and graft survival based on MVI (+) and MVI (−) at last follow‐up were outcomes of interest.
Results
A total of 108 KTRs transplanted between 2013 and 2022 fulfilled our selection criteria, 75 (69%) were MVI (+) and 33 (31%) MVI (−). Most baseline characteristics were similar between the groups. In Cox regression analysis, none of the commonly assessed baseline characteristics, Banff scores, or DSA status at first or second biopsy were associated with persistent MVI on the third biopsy. Also, in Cox regression analysis, after adjusting for various characteristics, persistent MVI on third biopsy was not associated with increased or decreased risk for uncensored graft failure (aHR: 0.55, 95% CI: 0.23–1.29; p = 0.17).
Conclusion
The lack of difference in graft outcomes between the AMR patients who were MVI (+) versus MVI (−) on the third biopsy suggests that subsequent response to AMR treatment is less important for prognosis than the initial development of AMR. This reinforces the importance of the prevention of rejection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Nephrology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
- Department of Pathology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
ORCID-Profile: Sandesh Parajuli, Adam Bregman, Neetika Garg, Didier Mandelbrot
Förderung
- the Virginia Lee Cook Foundation
Zitieren
APA
Parajuli, S., Bregman, A., Zona, E. E., Sokup, M., Garg, N., Zhong, W., & Mandelbrot, D. (2025). Outcomes of Persistent Microvascular Inflammation in Repeated Kidney Allograft Biopsies. Clinical Transplantation, 39(12). https://doi.org/10.1111/ctr.70419
Vancouver
Parajuli S, Bregman A, Zona EE, Sokup M, Garg N, Zhong W, et al. Outcomes of Persistent Microvascular Inflammation in Repeated Kidney Allograft Biopsies. Clinical Transplantation. 2025;39(12). doi:10.1111/ctr.70419
BibTeX
@article{Parajuli2025,
author = {Parajuli, Sandesh and Bregman, Adam and Zona, Emily E and Sokup, Megan and Garg, Neetika and Zhong, Weixiong and Mandelbrot, Didier},
title = {Outcomes of Persistent Microvascular Inflammation in Repeated Kidney Allograft Biopsies},
journal = {Clinical Transplantation},
year = {2025},
volume = {39},
number = {12},
doi = {10.1111/ctr.70419}
}
EUVIMED